abstract: Prostaglandins participate in a variety of female reproductive processes, including ovulation, fertilization, embryo implantation and parturition. In particular, maternal prostacyclin (PGI 2 ) is critical for embryo implantation and the action of PGI 2 is not mediated via its G-protein-coupled membrane receptor, IP, but its nuclear receptor, peroxisome-proliferator-activated receptor d (PPARd). Recently, several studies have shown that PGI 2 enhances blastocyst development and/or hatching rate in vitro, and subsequently implantation and live birth rates in mice. However, the mechanism by which PGI 2 improves preimplantation embryo development in vitro remains unclear. Using molecular, pharmacologic and genetic approaches, we show that PGI 2 -induced PPARd activation accelerates blastocyst hatching in mice. mRNAs for PPARd, retinoid X receptor (heterodimeric partners of PPARd) and PGI 2 synthase (PGIS) are temporally induced after zygotic gene activation, and their expression reaches maximum levels at the blastocyst stage, suggesting that functional complex of PPARd can be formed in the blastocyst. Carbaprostacyclin (a stable analogue of PGI 2 ) and GW501516 (a PPARd selective agonist) significantly accelerated blastocyst hatching but did not increase total cell number of cultured blastocysts. Whereas U51605 (a PGIS inhibitor) interfered with blastocyst hatching, GW501516 restored U51605-induced retarded hatching. In contrast to the improvement of blastocyst hatching by PPARd agonists, PPAR antagonists significantly inhibited blastocyst hatching. Furthermore, deletion of PPARd at early stages of preimplantation mouse embryos caused delay of blastocyst hatching, but did not impair blastocyst development. Taken together, PGI 2 -induced PPARd activation accelerates blastocyst hatching in mice.
Introduction
Prostaglandins (PGs) participate in a variety of cellular functions, including modulation of vascular tone, cell proliferation, apoptosis and differentiation Dey, 2000, 2002; Dey et al., 2004) . Cyclooxygenases (COX-1 and COX-2) are the rate-limiting enzymes in the synthesis of PGs by mediating the conversion of arachidonic acid into PGH 2 , which is then converted to various PGs by specific synthases. Multiple reproductive failures in COX-2-deficient female mice have demonstrated that PGs are critical for various female reproductive processes, including ovulation, fertilization and embryo implantation (Lim et al., 1997) . In particular, maternally derived prostacyclin (PGI 2 ) is an essential factor for embryo implantation in mice. While the action of PGI 2 is generally mediated via its G-protein-coupled membrane receptor, IP, critical roles of PGI 2 in embryo implantation and decidualization are mediated via its nuclear receptor, peroxisome proliferator-activated receptor d (PPARd) (Lim et al., 1999; Ding et al., 2003) .
PPAR family of transcription factors (PPARa, PPARg and PPARd) belongs to the nuclear hormone superfamily (Huang, 2008) . The identification of PPAR as a receptor for liver peroxisome proliferators stimulated extensive investigations regarding the role of these receptors in lipid metabolism and homeostasis. Transcriptional activation of target genes by PPARs depends on ligand-induced heterodimerization with a retinoid X receptor (RXR) and recruitment of several cofactors that are shared by various nuclear hormone receptors (Lim and Dey, 2002; Lim et al., 2004; Huang, 2008) , implicating the complex signalling networks of PPARs. Three PPAR isoforms exhibit different expression patterns and ligand dependency. PPARa is highly expressed in the liver and is implicated in lipid homeostasis. PPARg is mainly expressed in white adipose tissue and is implicated in adipocyte differentiation. PPARd participates in many biological processes, including lipid and glucose metabolism, wound healing, tumorigenesis and inflammation.
Several recent studies have demonstrated that PGI 2 is the most abundant PG produced by oviductal epithelial cells in humans and mice, and facilitates blastocyst development and hatching of in vitro cultured mouse embryos (Huang et al., 2002 (Huang et al., , 2004a . Human embryos co-cultured with homologous oviduct cells had higher hatching rates. Oviduct epithelial cells express enzymes crucial to PGI 2 synthesis, COX-1, COX-2 and PGI 2 synthase (PGIS) in humans and mice, and can produce a large amount of PGI 2 when incubated with excess arachidonic acid (Huang et al., 2002 (Huang et al., , 2004a . In addition, PGI 2 seems to enhance implantation and live birth potentials of in vitro cultured embryos (Huang et al., 2004b) . A recent study has suggested that PGI 2 -mediated PPARd activation is critical to cell proliferation of preimplantation embryos, and PPAR deficiency leads to impaired cell proliferation and subsequently delayed blastocyst development and hatching (Huang et al., 2007b) . In contrast, another report has shown that PGI 2 does not increase the cell numbers of in vitro cultured blastocysts, while it enhances blastocyst development and hatching . Thus, it still remains unclear whether PGI 2 -induced PPARd activation facilitates cell proliferation, leading to advances of blastocyst development and hatching. In this paper, using genetic, pharmacologic and molecular approaches, we demonstrate that ligand-induced activation of PPARd facilitates blastocyst hatching without a significant change in embryonic cell number.
Materials and Methods

Collection of eggs and preimplantation embryos
Four-week-old C57BL6 or ICR female mice were bred with adult male mice (Orient Bio, Seongnam, Korea). Mice were housed with the lights on for 12 h daily and fed ad libitum. Superovulation was induced by a standard hormone treatment using an intraperitoneal injection of 5 IU pregnant mare's serum gonadotrophin (Sigma, St. Louis, MO, USA) followed by 5 IU human chorionic gonadotrophin (Sigma) 48 h later. After mating overnight with fertile males, females were inspected for vaginal plugs the next morning and sacrificed at appropriate times for each experiment. Two-cell embryos and blastocysts were harvested from oviducts and uteri, respectively and cultured in M16 medium supplemented with 0.1% bovine serum albumin (BSA; M16 + BSA). For embryo RNA extraction, embryos at a variety of developmental stages were collected, washed and stored in TRIzol reagent (Invitrogen, Carlsbad, CA, USA) until use.
RNA extraction and RT-PCR
Total RNA was isolated from 20 pooled embryos using TRIzol reagent according to the manufacturer's protocol. One microgram glycogen was added before RNA extraction to enhance the isolation efficiency of embryo RNA. For the external reference, rabbit a globin mRNA was also added before RNA extraction. Total RNA was pelleted by centrifugation, washed using 1 ml of 75% ethanol and dissolved in RNase-free water. Total RNA isolated from embryos at various developmental stages was subjected to RT using Moloney murine leukaemia virus (MMLV) reverse transcriptase (Roche Applied Science, Indianapolis, IN, USA) for cDNA synthesis. RNA was denaturated at 958C for 5 min and reverse transcriptase was added at 428C for 60 min in 20 ml reaction mixture consisting of 1X RNA PCR buffer, 1 mM dNTPs, 2.5 mM oligo dT primer, 1 unit/ml RNasin ribonuclease inhibitor and 2.5 unit/ml MMLV reverse transcriptase. After the reaction was conducted at 958C for 5 min, samples were stored at 2708C until the PCR. One microlitre of RT product (1 equivalent of single embryo) was used for RT -PCR with specific primers at optimized cycles (MyCycler, Bio-Rad Laboratories, Hercules, CA, USA). The primer sequences and size of the amplicons are listed in Table I 
Statistics
Fisher's exact test or student's t-test was performed to examine statistical significance (*, P , 0.05; **,0.01).
Results
PPARd and its heterodimeric partners are temporally expressed during preimplantation embryo development
Using RT-PCR, we have examined whether PPARd and other members of PPAR family (PPARa and PPARg) are expressed in preimplantation mouse embryos. PPARd is predominantly expressed among three members of PPAR family (Fig. 1A) . PPARd mRNA was detected at the pronuclear stage, suggesting that there is maternal PPARd mRNA. While PPARd expression from 8-cell stage onwards was predominantly induced at the blastocyst stage, PPARa and PPARg are not expressed in preimplantation embryos after zygotic gene activation. To function as a receptor for PGI 2 , PPARd has to recruit one of RXRs as its heterodimeric partner. Thus, we have examined temporal expression patterns of RXR family members (a, b, g) during preimplantation embryo development (Fig. 1B) . Among three RXR members, RXRa was predominantly expressed and its expression significantly increased at the blastocyst stage. RXRb had expression patterns similar to that of RXRa at much lower levels and RXRg mRNA levels were very low to undetectable. Furthermore, we examined temporal expression patterns of PGIS and IP, membrane receptor for PGI 2 during preimplantation embryo development (Fig. 1C) . PGIS mRNA was expressed from morula stage and its level increased at the blastocyst stage. Whereas PPARd was highly expressed at the blastocyst stage, IP expression was very low or undetectable. Collectively, these results suggest that PPARd-RXR transcriptional complex could be formed to mediate PGI 2 actions during preimplantation embryo development.
cPGI and a PPARd selective agonist significantly accelerates blastocyst hatching in vitro
To examine whether PGI 2 -PPARd-RXR complex facilitates blastocyst formation and subsequent hatching in mouse embryos, superovulated 2-cell stage embryos were cultured with a stable analogue of PGI 2 , Figure 1 RT-PCR analyses of PPARs, RXRs, PGIS and IP in preimplantation embryos. RT -PCR was performed with specific primers for (A) PPAR (B) RXR and (C) PGIS and IP at optimized cycles. Equal amount of rabbit a-globin mRNA was added before embryo RNA preparation, and used as external control to compare efficiency of RNA preparation for each sample. These experiments were repeated three times with independent sample sets and similar results were obtained. 1, 2, 4 and 8 indicate 1, 2, 4 and 8 cell embryos, respectively. Mo, Bl, hBl, PC and NC indicate morula, blastocyst, hatched blastocyst, positive control and negative control, respectively. Primer sequences are shown in Table I. cPGI or a selective PPARd agonist, GW501516. While the blastocyst formation rate of embryos cultured with cPGI did not reach statistical significance, both cPGI and GW501516 increased blastocyst formation rates 48 h later (Day 4) ( Fig. 2A) . Furthermore, cPGI and GW501516 clearly accelerated blastocyst hatching 96 h after treatment (Day 6) ( Fig. 2B) , suggesting that PGI 2 action on blastocyst hatching is mediated via its nuclear receptor, PPARd in mice. Since blastocyst hatching is influenced by the cell number of blastocyst (Montag et al., 2000) , total cell number of blastocysts cultured with either cPGI or GW501516 were counted at 96 h after treatment. Whereas cPGI and GW501516 accelerated blastocyst hatching, neither cPGI nor GW501516 significantly increased total cell number of blastocysts ( Fig. 2C and D) . These results suggested that accelerated blastocyst hatching is not directly associated with the cell number of blastocysts in mice.
Activation of PPARd reverses inhibitory effects of a PGIS inhibitor, U51605 on blastocyst hatching
To examine whether activation of PPARd signalling pathway is critical for blastocyst hatching in mice, blastocysts were cultured with U51605, a PGIS inhibitor or with U51605 + GW501516, and then their hatching was evaluated from 48 to 96 h later. U51605 significantly interfered with initiation of blastocyst hatching (Fig. 3) although it did not affect blastocyst development of 2-cell embryos (data not shown). Addition of GW501516 effectively reversed inhibitory effects of U51605 on blastocyst hatching, suggesting that the function of PGI 2 on blastocyst hatching is mediated via its nuclear receptor PPARd.
PPAR antagonists interfere with blastocyst hatching in mice
To further examine whether advanced blastocyst hatching is associated with PPARd activation, Day 4 blastocysts were collected and cultured with PPAR antagonists for 48 h. Since PPARd-specific antagonist is not commercially available, and PPARa and PPARg are not expressed in preimplantation embryos (Fig. 1A) , PPAR antagonists, GW9662 and T0070907, which have more potent inhibitory effects on PPARg and/or PPARa were used to interfere with blastocyst hatching. Hatching rates of blastocysts treated with either GW9662 or T0070907 were significantly reduced 48 h after treatment (Fig. 4A) . Whereas a few blastocysts failed to initiate hatching in control, many blastocysts treated with either GW9662 or T0070907 did not show any sign of hatching and were entirely encased by zona pellucida (arrowheads in Fig. 4) . Total cell number of blastocysts cultured with GW9662 or T0070907 was similar to that of control blastocysts (Fig. 4C and D) . PPARd(ck/ck) embryos regardless of the presence of tamoxifen (Fig. 5B) . In contrast to the blastocyst development, blastocyst hatching was significantly delayed in PPARd(ck/ck):Cre-ER TM embryos cultured with tamoxifen (Fig. 5C ). In addition, complete hatching rate of PPARd(ck/ck):Cre-ER TM embryos treated with tamoxifen was significantly reduced (data not shown). On the other hand, the total cell Figure 3 Inhibitory effect of U51605, a PGIS inhibitor, on blastocyst hatching is reversed by PPAR agonist GW501516. Day 4 blastocysts were collected and cultured with 6 mM U51605 (U) and/or 5 mM GW501516 (G) for 48 h and their hatching rates were compared between groups. Three independent experiments were performed and similar results were obtained (total number of embryos in each group, n ¼ 59 -63). Note that GW501516 reversed inhibitory effects of U51605 on blastocyst hatching. Values with different letters were significantly different (P , 0.05). Total cell number of blastocysts treated with PPAR antagonist for 48 h. Day 6 blastocysts were stained with Hoechst to count cell number. Arrowheads indicate blastocysts completely enclosed by zona pellucida on day 6 in vitro. **indicate P , 0.01 and the graph in C represents mean + SD.
PPARd deletion at preimplantation stages delays blastocyst hatching
Activation of PPARd in blastocyst hatching number of tamoxifen-treated PPARd deficient blastocysts were not different from that of PPARd(ck/ck) blastocysts (Fig. 5D) . Collectively, deletion of PPARd at early preimplantation stages leads to delayed blastocyst hatching without significant changes in cell number.
Discussion
PGs are well known to be critical for multiple events of female reproductive events from ovulation to parturition (Lim et al., 1997 (Lim et al., , 1999 Reese et al., 1999 Reese et al., , 2001 Lim and Dey, 2000; Dey et al., 2004; Wang et al., 2007) . Previously, we have shown that among PGs, COX-2-derived PGI 2 mediates blastocyst implantation via its nuclear receptor, PPARd in mice (Lim et al., 1999) . Here, we demonstrated that PGI 2 facilitates blastocyst development and hatching via its nuclear receptor PPARd without a significant change in the total cell number in mice. Our works collectively suggested that the activation of PPARd is important for blastocyst hatching in the embryo as well as blastocyst implantation in the uterus in mice. Our RT -PCR results showed that PPARa and PPARg are not expressed in preimplantation mouse embryos after zygotic gene activation. It is consistent with the results of a previous work that selective agonists for PPARa and PPARg do not have any effects on blastocyst development and hatching in mice (Huang et al., 2007b) . Since PPARa and PPARg are not expressed in preimplantation embryos, PPAR antagonists that have more potency to inhibit PPARa and PPARg than PPARd were used in this study, and they effectively interfered with blastocyst hatching. To regulate its target genes important for blastocyst development and hatching, PPARd is required to form a heterodimer with one of RXRs (Lim et al., 1999; Lim and Dey, 2000; Huang, 2008) . We demonstrate that RXRs, especially RXRa, as well as PPARd, are expressed in preimplantation mouse embryos with a peak level at the blastocyst stage, suggesting that they may regulate the expression of target genes important for preimplantation embryo development. In fact, good quality embryos express significantly higher levels of RXR mRNA transcripts than bad quality embryos in bovine preimplantation embryos (Mamo et al., 2005) . Collectively, concomitant expression of PPARd, RXRs and PGIS at the blastocyst stage suggested that PGI 2 -induced PPARd activation is involved in blastocyst hatching in mice.
It has been proposed that blastocyst hatching is mediated by two major factors: a crucial increase of cell number in embryos (Montag et al., 2000) and the digestion of zona pellucida by proteolytic enzymes (Sawada et al., 1990) . There have been many reports that proteolytic processes with a variety of proteases are involved in blastocyst hatching although it still remains unclear. The cysteine proteases, cathepsin L and P, are expressed in blastocyst and functionally involved in blastocyst hatching in golden hamster (Sireesha et al., 2008) . Two implantation serine proteases, ISP1 and ISP2, and other proteases such as plasminogen activators and matrix metalloproteases have been proposed to play a role in the hatching process (Seshagiri et al., 2003; Aflalo et al., 2005; Sharma et al., 2006) . Barak et al. suggested that imbalance in extracellular matrix remodelling caused by either insufficient or excessive proteolysis in PPARd knockout post-implantation embryos could cause the breakdown of the placento-decidual interface (Barak et al., 2002) . This implicates that PGI 2 -induced PPARd activation may regulate the expression of a number of proteases that could be involved in proteolytic process of blastocyst hatching. PPARd agonist induces a massive differentiation of trophoblast giant cells via Akt phosphorylation during placenta development (Nadra et al., 2006) . Interestingly, inhibition of PI3K/Akt signalling pathway resulted in a significant delay in blastocyst hatching (Riley et al., 2005) . Further investigation to understand downstream pathways of PPARd in blastocyst hatching will be required for the clinical application of PPARd selective agonists to improve human IVF cycles suffering from hatching problems such as zona hardening.
Using multiple approaches including a conditional knock out model, we demonstrated that PPARd activation facilitates blastocyst hatching without significant changes in cell numbers in mice. However, a recent study using conventional PPARd knockout embryos has shown that PPARd deficiency causes severely impaired cell proliferation, subsequently leading to poor blastocyst development and delayed hatching (Huang et al., 2007b) . This discrepancy in phenotypes of two different PPARd knockout mouse models could be due to the maternal effects of PPARd deficiency. In fact, quality improvement of oocyte matured in vitro enhances blastocyst development and hatching in mice (Yeo et al., 2008) . There are many evidences that maternal deficiency of growth factors, cytokines and transcription factors results in suboptimal or poor quality of oocyte and subsequent embryo development (Panic et al., 2006; Huang et al., 2007a; Sun et al., 2008; Yeo et al., 2008) . For example, the different developmental potentials of IP(+/2) embryos derived from IP( -/ -) oocytes or IP( -/ -) sperm support this rationale. Whereas IP(+/ -) embryos derived from IP( -/-) sperm develop as competently as IP(+/+) embryos, IP(+/2) embryos derived from IP( -/ -) oocytes showed retarded early embryo development (Huang et al., 2007a) . It clearly suggested that lagged development of IP(+/2) embryos from IP( -/ -) oocytes but not IP( -/ -) sperm could be originated from defective oocyte development caused by IP deficiency in oocytes and/or somatic cells during follicle development.
Thus, PPARd deficiency in oocyte and/or somatic cells in developing follicles could affect the quality of oocytes, possibly resulting in impaired cell proliferation in the embryo. Such defects in proliferation and/or survival of blastomeres in the embryo may negatively influence following embryo development and blastocyst hatching in conventional PPARd knock-out embryos. Indeed, blastocyst hatching in vitro is dependent on a sufficiently high number of embryonic cells (Montag et al., 2000) . In the present study using PPARd conditional knock out model in which PPARd is deleted from 2-cell stage, we could deviate this phenomenon and provide the evidence that PGI 2 -induced PPARd activation is important for blastocyst hatching, but does not significantly influence cell proliferation and/or apoptosis in preimplantation mouse embryos. Collectively, these two PPARd mouse models suggest that PPARd is critical for oocyte quality with subsequent embryo development and blastocyst hatching for implantation.
